Identifying New Memory and Brain Markers for Early Alzheimer's Disease

Project Summary

Despite newly available treatments for Alzheimer’s disease, dementia subtype specificity is important to determine prior to treatment to ensure safe and efficacious outcomes. Optimized cognitive assessments and imaging biomarkers are also essential for early detection and to monitor disease progression.  

This project will address these challenges by developing new cognitive and neural markers sensitive to the early effects of Alzheimer’s. These markers can be used to screen for subtle memory changes, classify by subtype, and identify signatures of healthy brain function that can clarify mechanisms of disease-modifying effects on memory in early-phase clinical trials.